Sat.Oct 01, 2022

article thumbnail

New report ignores benefits of patent system to innovation and patients

PhRMA

A recent report from the Initiative for Medicines, Access & Knowledge – known as I-MAK – highlights fundamental misunderstandings about America’s patent system and how it benefits patients and medical innovation. I-MAK accuses biopharmaceutical companies of blocking competition and gaming the system by patenting new innovations, when in reality, new patents do not extend old patents, and they do not prevent competitors from launching new products.

249
249
article thumbnail

NCPA Recommends Prescryptive Health AI-Optimized Pricing System to Community Pharmacists

Drug Topics

MyRx AI Pricing uses enhanced analytics to bring dynamic pricing to pharmacies and cash-paying customers.

183
183
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Generic Product News: September 2022

Pharmacy Times

This month's generic product news features clorazepate dipotassium tablets, exemestane tablets, and paliperidone extended-release tablets.

149
149
article thumbnail

Pharmacists Can Prescribe Birth Control in Michigan, in Partnership with Physicians

Drug Topics

The move is meant to expand access to reproductive health care for women in the state.

187
187
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Combination of Ivosidenib Plus Azacitidine Produces Survival Benefit in Acute Myeloid Leukemia

Pharmacy Times

Ivosidenib plus azacitidine shows benefits in event-free survival, overall survival, and clinical responses compared with placebo in patients with IDH1-mutated acute myeloid leukemia.

122
122
article thumbnail

Grow Front-End Sales Today With These High-Impact, Low Cost Tips

Drug Topics

Take in these top tips for pharmacy front-end management.

187
187

More Trending

article thumbnail

ALS Therapy Approved by FDA

Drug Topics

Now with the brand name Relyvrio, the new therapy should be available within four to six weeks. It will have a wholesale acquisition cost of $158,000 per year.

FDA 98
article thumbnail

Celebrating Pharmacists During American Pharmacists Month 2022

Pharmacy Times

Pharmacy Times will be spotlighting pharmacists throughout the month of October to recognize their contributions to the health care field.

168
168
article thumbnail

The Death Knell of Pharma HCP Websites

PharmExec

Should pharma brands still maintain dedicated websites to engage HCPs? Are they effective and trustworthy sources of information that offer intuitive and helpful experiences for the user?

98
article thumbnail

Pharmacy Focus Episode 56: How to Enhance the Patient Experience Through Integrated Care Models

Pharmacy Times

Willoughby hopes on a global standpoint that every chronic condition patient has access to a support team that is there to provide care.

121
121
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

FDA grants approval for Amylyx’s Relyvrio to treat ALS

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval for Amylyx Pharmaceuticals’ Relyvrio (sodium phenylbutyrate and taurursodiol) to treat adult patients with amyotrophic lateral sclerosis (ALS). Indicated for use as a monotherapy or along with currently approved therapies, Relyvrio can be administered orally by mixing a packet in eight ounces of water.

FDA 97
article thumbnail

Peptide-Based Cancer Vaccines May Offer Effective Protection Against Aggressive Tumors

Pharmacy Times

New research in immunotherapy is exploring vaccines to treat cancer, whether preventative or reactive against current tumors.

Vaccines 123
article thumbnail

Frontiers Health Steering Committee spotlight: Eugene Borukhovich

pharmaphorum

With Frontiers Health 2022 mere weeks away, we continue to interview members of the steering committee, gaining insight into what to expect from Milan. In this latest coverage, pharmaphorum speaks with Eugene Borukhovich. Formerly global head of digital health at Bayer, these days Borukhovich is travelling the entrepreneurial path, co-founder and COO of YourCoach.Health, together with his wife, Marina, who is also herself a health coach.

article thumbnail

Adlarity From Corium

Pharmacy Times

Indicated for the management of mild, moderate, and severe Alzheimer disease and dementia symptoms, the donepezil transdermal system (Adlarity; Corium) delivers donepezil hydrocholoride through the skin and is recommended at an initial dosage of 5 mg per day.

Dosage 91
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

STAT+: Up and down the ladder: The latest comings and goings

STAT

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.  That’s right. Send us your changes, and we’ll find a home for them.   Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

98
article thumbnail

Comparative Pharmacology: MDMA, Psilocybin, and Ketamine

The Spirit Pharmacist

This vlog features a sneak peek at a content module from one of my courses titled ' Breakthrough Psychedelics: MDMA, Psilocybin, and Ketamine ' and is a summary discussion that compares and contrasts the pharmacology and clinical characteristics of MDMA, psilocybin, and ketamine. It's a helpful place to start for a summary narrative of pharmacology and clinical potential of Breakthrough Psychedelics, and I know a lot of you are interested in going deeper and taking your knowledge of these psyche

96
article thumbnail

STAT+: Pharmalittle: FDA approves a medicine to combat ALS; Medicare drug-price talks are poised to become a legal battle

STAT

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, to be honest. We do, however, hope to find time to catch up on our reading, have a listening party with Mrs. Pharmalot, and, of course, promenade with our official mascot.

FDA 98
article thumbnail

Sharing data on human tissue availability across EU

European Pharmaceutical Review

The Committee of Ministers for the Council of Europe has adopted a recommendation for Member States to collate use and availability data for tissues and cells, so that immediate provision is granted to end users. Sharing data across borders ensures access to safe tissues and cells for human application is ethical and supply quality is adequate, said the Council in a statement.

article thumbnail

Student Pharmacist Spotlight: Kennedy Erickson

Drug Topics

Erickson shares her tips on managing burnout as a student pharmacist.

112
112
article thumbnail

CAR-T therapy safe for relapsed or refractory T-cell malignancies, finds study

European Pharmaceutical Review

Bioheng Biotech , a biotechnology firm that develops cellular immunotherapies, have issued key Phase I clinical trial (NCT04538599) results for the drug RD13-01, an anti-CD7 universal CAR-T therapy, establishing that it is safe for use and has the potential to eliminate malignant tumours. It is the first trial to use healthy donor-derived CD7-targeting allogeneic CAR T cells to treat CD7-positive haematological tumours.

article thumbnail

The 7 Most Common Nutrient Deficiencies in Hashimoto’s

The Thyroid Pharmacist

After my own Hashimoto’s diagnosis in 2009, I wanted to figure out what I could do to live the healthiest life possible. I wanted to know if there was anything I could do to address my symptoms and reverse my condition — or at least stop its progression. So, I set out on a journey to find the root cause of my disease. I have learned that Hashimoto’s symptoms result from a combination of thyroid hormone imbalances, nutrient deficiencies, food sensitivities, an impaired ability to handle stress, a

article thumbnail

Serplulimab increases survival in small cell lung cancer patients

European Pharmaceutical Review

A Phase III trial from Shanghai Henlius Biotech is the first study to suggest that the programmed cell death (PD) 1 receptor immune checkpoint inhibitor Hansizhuang (serplulimab) plus chemotherapy can markedly improve survival for extensive-stage small cell lung cancer (ES-SCLC) patients. The study called ASTRUM-005, led by Professor Ying Cheng from Jilin Cancer Hospital, China, compared the effectiveness and safety parameters of serplulimab combined with chemotherapy to placebo.

article thumbnail

Pharmacy Times and Parata Systems Announce the 2022 Next-Generation Pharmacist Award Winners

Pharmacy Times

Phoenix-area Walgreens pharmacist Matthew Pruitt earns top honor as 2022 Pharmacist of the Year.

106
106
article thumbnail

FDA Clarifies Naloxone Supply Chain Rules

Drug Topics

The new guidance aims to improve supply for harm reduction programs.

FDA 98
article thumbnail

Monjuvi Demonstrates Long-Term Efficacy for Individuals With R/R DLBCL

Pharmacy Times

Study results show that the frequency of adverse events decreased after the patients transitioned from combination therapy to monotherapy.

81
article thumbnail

News Roundup: September 26 to September 30

Drug Topics

Your weekly roundup of the latest news from Drug Topics®.

98
article thumbnail

Involved, Close Pathological Margins After Breast Conserving Surgery Associated With Increased Recurrence

Pharmacy Times

All of the findings indicate that inadequate margin widths result in higher risks of distant recurrence and breast cancer mortality, as well as increased total recurrence.

65
article thumbnail

Nitrogen dioxide for sterilisation of protein-filled polymer-based syringes

European Pharmaceutical Review

Researchers have shown that nitrogen dioxide (NO 2 ) gas sterilisation may be the most appropriate choice for the sterilisation of intravitreal injections (IVIs) packaged in polymer-based prefilled syringes (P-PFSs). In their work, the team compared the ingression of gas and the resulting physical and chemical degradation to a model protein in formulation, when sterilising with NO 2 , ethylene oxide (EO) and vaporized hydrogen peroxide (VHP).

article thumbnail

Belantamab Mafodotin Combination Shows Durable Efficacy in Relapsed or Refractory Multiple Myeloma

Pharmacy Times

Belantamab mafodotin plus lenalidomide and dexamethasone was found tolerable with no new safety signals and enhanced response rates in patients with multiple myeloma.

65
article thumbnail

Intercept hit hard as NASH trial misses the mark

pharmaphorum

Intercept Pharma’s hopes of getting its non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA) in the US may have taken another dive, after it flunked a phase 3 trial. Shares in the company lost around 16% of their value after the top-line result of the REVERSE study in patients with compensated NASH-related cirrhosis were announced, as investors tried to work out what the failure will mean for the drug’s prospects.

FDA 59
article thumbnail

National Community Pharmacists Association to Host Annual Convention, Emphasizing Teamwork

Pharmacy Times

Douglas Hoey, CEO of NCPA, discusses NCPA's Annual Convention 2022, which will be held in Kansas City, Missouri from October 1 to October 4.

65
article thumbnail

Babylon hires Andrew Hine to spearhead overseas expansion

pharmaphorum

UK digital health company Babylon has hired Andrew Hine to take charge of its international expansion efforts, as it fights to retain its stock market listing in the US. Andrew Hine via LinkedIn. Formerly partner and head of health for Middle East and North Africa (MENA) at accounting group Ernst & Young, Hine will head up Babylon’s go-to-market team for Europe, Middle East, and Africa (EMEA), as well as Asia.

59
article thumbnail

Understanding of Mutations Influences Treatment for Patients With Waldenstrom Macroglobulinemia

Pharmacy Times

Biology and disease type may help determine which therapeutic options could work best for patients with Waldenstrom macroglobulinemia.

65
article thumbnail

Pediatricians vs. Pediatric Nurse Practitioners: How Do They Compare? 

Board Vitals - Pharmacist

Pediatricians and Pediatric Nurse Practitioners specialize in caring for children from infancy throughout adolescence. While these healthcare professionals both care for children, there are different education requirements and scopes of practice involved. In this article we’ll take a look at some of the key similarities and differences between pediatricians and pediatric nurse practitioners.